Home -> Law Blog Directory -> Legal Commentary Blogs -> The Volokh Conspiracy
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Legal Commentary
: The Volokh ConspiracyRequiring OIRA Review of CFPB Actions:
By Todd Zywicki
This summer, shortly before Dodd-Frank was enacted, I offered several suggestions on how the new Bureau of Consumer Financial Protection could be made more consumer-friendly. Several of my concerns were based on my experience working at the Federal Trade Commission and studying the regulatory process. In particular, I noted the dangers presented by the almost complete lack of any oversight or checks and balances of the new super-regulator. Obviously my concerns were not reflected in the final legislation.
Another proposal that I didn?t discuss then but which I now offer (together with two of my colleagues from the Mercatus Center) is to subject CFPB actions to OIRA review. We offer the proposal in a Reuters column ?The Next Hot Ticket in Financial Reform.? We argue that although independent agencies (such as the Fed) typically are exempted from the OIRA review process, that is because they have internal checks and balances that mitigate some of the pathologies to which bureaucratic processes typically are prone. Notably, most independent agencies are headed by multi-member panels, often bipartisan in nature. While imperfect (as is OIRA review itself), it is at least arguable that this will provide some degree of deliberation and protection against tunnel vision and agency capture.
The CFPB, by contrast, is headed by one person with virtually unreviewable authority. It would be hard to imagine a bureaucratic design more susceptible to bureaucratic pathology than the CFPB. We argue that OIRA review might at least minimize some of the harm that the new Bureau inevitably is going to do to the economy and consumers.
Full post as published by The Volokh Conspiracy on October 09, 2010 (boomark / email).
FDA Issues Update on Safety Review Orlistat
Orlistat FDA Issues Update on Safety Review
Aurora Loan Faces Class Action over Mortgage Review Services
Aurora Loan Faces Class Action over Mortgage Review Services
FDA Review of Prostate Cancer Treatment Prompts Warning of Risk for Diabetes
Prostate Cancer Treatment FDA Review Prompts Warning of Risk for Diabetes
Xigris
Study Prompts FDA Safety Review
Lipitor
Review of Studies Show No Significant Benefit in Women
Wrinkle-Fillers
FDA to Review Labeling due to Adverse Event Reports

Senator Saxby Lifts "Hold" on Cass Sunstein for OIRA Position
House Conferees' Offer on CFPB Bill
What Should the CFPB Tackle First
President Obama and Cass Sunstein to take Hard Look at Proposed Rules
I Want the CFPB to Be Like Elizabeth Warren







